Cardiovascular Risk Assessment Tools are Insufficient for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Commonly used tools to identify CV risk performed poorly in a cohort of patients with MASLD. Because CV related death is the greatest source of mortality among patients with MASLD, better risk assessment tools are required.
Authors
- Heather Morris (ORCID: https://orcid.org/0000-0002-7540-5315)
- A. Sidney Barritt (ORCID: https://orcid.org/0000-0002-4200-3256)
- Elliot B. Tapper (ORCID: https://orcid.org/0000-0002-0839-1515)
- Philip N. Newsome (ORCID: https://orcid.org/0000-0001-6085-3652)
- Rohit Seth Loomba (ORCID: https://orcid.org/0000-0002-4845-9991)
- Anthony Perez (ORCID: https://orcid.org/0000-0002-8551-833X)
- Yestle Kim
- Derek Gazis
- Arun Jayant Sanyal (ORCID: https://orcid.org/0000-0001-8682-5748)
- Brent A. Neuschwander‐Tetri (ORCID: https://orcid.org/0000-0002-8520-7398)
- Andrea R. Mospan (ORCID: https://orcid.org/0000-0002-3419-8276)
Institutions
- University of North Carolina at Chapel Hill (US)
- Target (United States) (US)
- King's College - North Carolina (US)
- Virginia Commonwealth University (US)
- University of Michigan (US)
- University of California San Diego (US)
- Madrigal Pharmaceuticals (United States) (US)
- King's College Hospital (GB)
- Saint Louis University (US)
Publication Details
- Journal
- The American Journal of Gastroenterology
- Published
- 2025-06-11
- DOI
- https://doi.org/10.14309/ajg.0000000000003595
- Citations
- 2
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.71